Dolutegravir + Abacavir + Lamivudine 50 mg / 600 mg / 300 mg Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 50 mg / 600 mg / 300 mg
Reference Brands: Triumeq(US & EU)
Category: Anti Viral
Dolutegravir + Abacavir + Lamivudine, sold as Triumeq, is a once-daily HIV-1 treatment combining three antiretrovirals in one pill. It offers strong viral suppression, is FDA and EMA approved, and is recommended for patients who are HLA-B*5701 negative.
Product Description:
Dolutegravir + Abacavir + Lamivudine is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection. Marketed under the brand name Triumeq, this once-daily oral tablet combines Dolutegravir (an integrase inhibitor), Abacavir, and Lamivudine (both NRTIs) to block HIV replication and reduce viral load. Approved by the US FDA and EMA, it is recommended for adults and adolescents who are HLA-B*5701 negative, with no resistance to any of the components. Triumeq simplifies HIV treatment by combining three powerful agents in one pill, offering high efficacy, strong viral suppression, and improved adherence for long-term HIV management.
Dolutegravir + Abacavir + Lamivudine — third party manufacturing & bulk supply
Dolutegravir + Abacavir + Lamivudine 50 mg / 600 mg / 300 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Dolutegravir + Abacavir + Lamivudine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Dolutegravir + Abacavir + Lamivudine →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Dolutegravir, abacavir, and lamivudine are used together as a complete once-daily regimen for the treatment of HIV-1 infection in adults and adolescents. This fixed-dose combination helps suppress viral replication, improve immune function, and reduce the overall pill burden for patients requiring long-term antiretroviral therapy.
It is made from Dolutegravir, an integrase strand transfer inhibitor; Abacavir, a nucleoside reverse transcriptase inhibitor; and Lamivudine, another nucleoside reverse transcriptase inhibitor. These three components act through different mechanisms to stop HIV replication effectively.
The trade name for this combination is Triumeq.
Triumeq is manufactured by ViiV Healthcare.
The generic name is Dolutegravir + Abacavir + Lamivudine.
The brand name is Triumeq.
It is manufactured in the UK and Europe by ViiV Healthcare, while licensed generic versions are manufactured in India by approved pharmaceutical companies for global supply.
Related Products
Brincidofovir
Strength:
100 mg, 10 mg/ml
Form: Tablets / Oral suspension
Reference Brands: Tembexa (USA/EU)
View Details
Lenacapavir
Strength:
300 mg, 463.5 mg/1.5 mL
Form: Tablet / Injection
Reference Brands: Yeztugo (USA), Sunlenca (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
